Grippenet: A New Tool for the Monitoring, Risk-Factor and Vaccination Coverage Analysis of Influenza-Like Illness in Switzerland.
influenza
influenza-like illness
participatory surveillance
syndromic surveillance
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
27 Jun 2020
27 Jun 2020
Historique:
received:
30
04
2020
revised:
16
06
2020
accepted:
23
06
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
Implemented in Switzerland in November 2016, Grippenet provides Internet-based participatory surveillance of influenza-like illness (ILI). The aim of this research is to test the feasibility of such a system and its ability to detect risk factors and to assess ILI-related behaviors. Participants filled in a web-based socio-demographic and behavioral questionnaire upon registration, and a weekly symptoms survey during the influenza season. ILI incidence was calculated weekly, and risk factors associated to ILI were analyzed at the end of each season. From November 2016 to May 2019, 1247 participants were included. The crossing of the Sentinel System (Sentinella) epidemic threshold was associated with an increase or decrease of Grippenet ILI incidence, within the same week or earlier. The number of active users varied according to ILI incidence. Factors associated with ILI were: ages 0-4 compared with 5-14 (adjusted odds ratio (AOR) 0.6, 95% confidence interval (CI) 0.19-0.99), 15-29 (AOR 0.29, 95% CI 0.15-0.60), and 65+ (AOR 0.38, 95% CI 0.16-0.93); female sex (male AOR 0.81, 95% CI 0.7-0.95); respiratory allergies (AOR 1.58, 95% CI 1.38-1.96), not being vaccinated (AOR 2.4, 95% CI 1.9-3.04); and self-employment (AOR 1.97, 95% CI 1.33-3.03). Vaccination rates were higher than those of the general population but not high enough to meet the Swiss recommendations. Approximately, 36.2% to 42.5% of users who reported one or more ILIs did not seek medical attention. These results illustrate the potential of Grippenet in complementing Sentinella for ILI monitoring in Switzerland.
Identifiants
pubmed: 32605076
pii: vaccines8030343
doi: 10.3390/vaccines8030343
pmc: PMC7565003
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Influenza Other Respir Viruses. 2013 Jul;7(4):546-58
pubmed: 22897919
Euro Surveill. 2007 Jul 01;12(7):E5-6
pubmed: 17991409
Euro Surveill. 2017 Apr 6;22(14):
pubmed: 28422004
PLoS One. 2013 May 17;8(5):e64156
pubmed: 23691162
J Infect Dis. 2016 Dec 1;214(suppl_4):S386-S392
pubmed: 28830105
Health Serv Res. 2006 Jun;41(3 Pt 1):819-36
pubmed: 16704514
BMC Public Health. 2013 Sep 24;13:881
pubmed: 24063523
JMIR Public Health Surveill. 2017 Sep 19;3(3):e66
pubmed: 28928112
Epidemics. 2015 Dec;13:28-36
pubmed: 26616039
Bull World Health Organ. 2018 Aug 1;96(8):558-567
pubmed: 30104796
BMC Public Health. 2010 Oct 27;10:650
pubmed: 20979640
Euro Surveill. 2018 Mar;23(11):
pubmed: 29560854
Vaccine. 2009 Oct 23;27(45):6353-7
pubmed: 19840672
BMC Public Health. 2006 Oct 04;6:242
pubmed: 17018161
JMIR Public Health Surveill. 2017 Oct 11;3(4):e62
pubmed: 29021131
BMC Infect Dis. 2014 May 01;14:232
pubmed: 24885043
Infect Dis (Lond). 2016 Apr;48(4):322-327
pubmed: 26654752
Hum Vaccin Immunother. 2014;10(3):536-43
pubmed: 24343049